Browse FBLN1

Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix.
Domain PF12662 Complement Clr-like EGF-like
PF07645 Calcium-binding EGF domain
Function

Incorporated into fibronectin-containing matrix fibers. May play a role in cell adhesion and migration along protein fibers within the extracellular matrix (ECM). Could be important for certain developmental processes and contribute to the supramolecular organization of ECM architecture, in particular to those of basement membranes. Has been implicated in a role in cellular transformation and tumor invasion, it appears to be a tumor suppressor. May play a role in haemostasis and thrombosis owing to its ability to bind fibrinogen and incorporate into clots. Could play a significant role in modulating the neurotrophic activities of APP, particularly soluble APP.

> Gene Ontology
 
Biological Process GO:0001933 negative regulation of protein phosphorylation
GO:0007162 negative regulation of cell adhesion
GO:0007565 female pregnancy
GO:0007566 embryo implantation
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010771 negative regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010812 negative regulation of cell-substrate adhesion
GO:0010952 positive regulation of peptidase activity
GO:0022604 regulation of cell morphogenesis
GO:0030198 extracellular matrix organization
GO:0031589 cell-substrate adhesion
GO:0034446 substrate adhesion-dependent cell spreading
GO:0040013 negative regulation of locomotion
GO:0042326 negative regulation of phosphorylation
GO:0043062 extracellular structure organization
GO:0043409 negative regulation of MAPK cascade
GO:0044706 multi-multicellular organism process
GO:0045862 positive regulation of proteolysis
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0051271 negative regulation of cellular component movement
GO:0052547 regulation of peptidase activity
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070373 negative regulation of ERK1 and ERK2 cascade
GO:0072089 stem cell proliferation
GO:0072091 regulation of stem cell proliferation
GO:0072376 protein activation cascade
GO:0072378 blood coagulation, fibrin clot formation
GO:1900024 regulation of substrate adhesion-dependent cell spreading
GO:1900025 negative regulation of substrate adhesion-dependent cell spreading
GO:1902532 negative regulation of intracellular signal transduction
GO:2000146 negative regulation of cell motility
GO:2000647 negative regulation of stem cell proliferation
Molecular Function GO:0001968 fibronectin binding
GO:0005201 extracellular matrix structural constituent
GO:0008022 protein C-terminus binding
GO:0008047 enzyme activator activity
GO:0016504 peptidase activator activity
GO:0061134 peptidase regulator activity
GO:0070051 fibrinogen binding
Cellular Component GO:0005577 fibrinogen complex
GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0044420 extracellular matrix component
GO:0071953 elastic fiber
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1566948: Elastic fibre formation
R-HSA-1474244: Extracellular matrix organization
R-HSA-2129379: Molecules associated with elastic fibres
Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FBLN1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FBLN1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FBLN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-2.4690.000806
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-3.4180.222
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-1.7660.373
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2920.659
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3250.919
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2570.946
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3610.565
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5510.752
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1080.957
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2910.886
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.2330.387
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0490.803
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FBLN1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FBLN1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FBLN1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FBLN1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FBLN1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FBLN1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FBLN1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFBLN1
Namefibulin 1
Aliases FBLN; FIBL1; FIBL-1; Fibulin-1
Chromosomal Location22q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FBLN1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.